HomeCompareBFRA vs ADC

BFRA vs ADC: Dividend Comparison 2026

BFRA yields 4.72% · ADC yields 4.11%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ADC wins by $149.7K in total portfolio value· pulled ahead in Year 3
10 years
BFRA
BFRA
● Live price
4.72%
Share price
$2.67
Annual div
$0.13
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$27.3K
Annual income
$638.40
Full BFRA calculator →
ADC
Agree Realty Corporation
● Live price
4.11%
Share price
$75.38
Annual div
$3.10
5Y div CAGR
40.4%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$176.9K
Annual income
$79,647.25
Full ADC calculator →

Portfolio growth — BFRA vs ADC

📍 ADC pulled ahead of the other in Year 3

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodBFRAADC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, BFRA + ADC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
BFRA pays
ADC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

BFRA
Annual income on $10K today (after 15% tax)
$401.12/yr
After 10yr DRIP, annual income (after tax)
$542.64/yr
ADC
Annual income on $10K today (after 15% tax)
$349.45/yr
After 10yr DRIP, annual income (after tax)
$67,700.16/yr
At 15% tax rate, ADC beats the other by $67,157.52/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of BFRA + ADC for your $10,000?

BFRA: 50%ADC: 50%
100% ADC50/50100% BFRA
Portfolio after 10yr
$102.1K
Annual income
$40,142.82/yr
Blended yield
39.32%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ADC right now

BFRA
Analyst Ratings
1
Buy
Consensus: Buy
ADC
Analyst Ratings
1
Strong
22
Buy
9
Hold
Consensus: Buy
Price Target
$81.06
+7.5% upside vs current
Range: $75.00 — $84.50
Altman Z
1.6
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

BFRA buys
0
ADC buys
0
No recent congressional trades found for BFRA or ADC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricBFRAADC
Forward yield4.72%4.11%
Annual dividend / share$0.13$3.10
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%40.4%
Portfolio after 10y$27.3K$176.9K
Annual income after 10y$638.40$79,647.25
Total dividends collected$5.6K$154.7K
Payment frequencyquarterlymonthly
SectorStockREIT
Analyst consensusBuyBuy

Year-by-year: BFRA vs ADC ($10,000, DRIP)

YearBFRA PortfolioBFRA Income/yrADC PortfolioADC Income/yrGap
1$11,172$471.91$10,987$577.21+$185.00BFRA
2$12,447$492.72$12,293$855.34+$154.00BFRA
3← crossover$13,831$513.03$14,088$1,290.70$257.00ADC
4$15,332$532.80$16,660$1,994.91$1.3KADC
5$16,957$551.98$20,525$3,181.85$3.6KADC
6$18,715$570.55$26,654$5,286.90$7.9KADC
7$20,613$588.49$37,006$9,259.47$16.4KADC
8$22,662$605.78$55,862$17,338.74$33.2KADC
9$24,871$622.42$93,452$35,300.32$68.6KADC
10$27,250$638.40$176,931$79,647.25$149.7KADC

BFRA vs ADC: Complete Analysis 2026

BFRAStock

Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that results in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of lesion-directed and field-directed actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos, an over-the-counter line of skin care cosmetic products. In addition, it is developing Ameluz for the treatment of field cancerization and nodular basal cell carcinoma. Further, the company's product portfolio includes Xepi, a prescription antibiotic cream for the treatment of impetigo; and Aktipak, a generic drug for the treatment of acne. It offers its products primarily in the United States, Europe, and Israel. The company has a collaboration and partnership agreement with Maruho Co., Ltd. Biofrontera AG was founded in 1997 and is headquartered in Leverkusen, Germany.

Full BFRA Calculator →

ADCREIT

Agree Realty Corporation is a publicly traded real estate investment trust primarily engaged in the acquisition and development of properties net leased to industry-leading retail tenants. As of September 30, 2020, the Company owned and operated a portfolio of 1,027 properties, located in 45 states and containing approximately 21.0 million square feet of gross leasable area. The Company's common stock is listed on the New York Stock Exchange under the symbol ADC.

Full ADC Calculator →
📬

Get this BFRA vs ADC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

BFRA vs SCHDBFRA vs JEPIBFRA vs OBFRA vs KOBFRA vs MAINBFRA vs NNNBFRA vs EPRTBFRA vs FCPT

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.